Reckitt's 15% Mead Johnson Panic May Have Left Core Brands on Sale

Mead Johnson litigation drove the sell-off, but the core business did not break

After the $60 million Mead Johnson verdict, Reckitt shares dropped more than 15% to a decade-low area. That kind of reaction is more typical of a blue-chip stock being reclassified as a legal-liability basket than of a fundamentally broken business.

Just as the panic spread, Reckitt's half-year results showed +2.7% core LFL net revenue growth and a 60.9% core gross profit margin. The operating backdrop behind brands such as Dettol and Lysol was still holding up. What changed sharply in the stock was not underlying business performance, but fear that the legal issue could spread across the group.

Investors are debating contained legal risk or a much larger liability wave

After the more than 15% one-day drop and an 18% year-to-date share-price decline, the market is asking whether Reckitt faces a few contained cases or a liability curve that could run far beyond the headline verdict.

The key question is exposure, not whether risk exists

Reuters has noted concerns that legal hits could be potentially reaching £2 billion, while Reuters also reported nearly 1,000 lawsuits are pending. That is enough to justify caution. It is a separate question whether the market is compressing a wide range of outcomes into one worst-case number.

That distinction matters because the docket is not moving in one direction. As of July, there were 810 active NEC lawsuits pending. At the same time, Abbott and Reckitt won a key Missouri case. If upcoming trials and management updates point toward containment, today's pricing may reflect more worst-case convergence than the evidence currently supports.

The bear case is procedural as much as substantive

The strongest bearish argument is procedural. An Illinois appellate court ruled the lawsuits can stay in the court where they were filed, preserving access to Madison County, a venue widely viewed as plaintiff-friendly. That matters because venue can shape settlement dynamics.

That pressure still looks material. There were 810 active NEC lawsuits pending, and market analysis has flagged legal hits potentially reaching £2 billion. Recent verdicts also keep concerns alive: Abbott just faced a $53 million verdict in Chicago. Bears will argue that the mix of venue, docket size, and multi-digit verdicts is exactly what turns this from an issue into a lasting overhang.

Mead Johnson verdicts do not automatically set the baseline

After the initial panic, the easier mistake is to treat verdict size as a proxy for ultimate liability. In this docket, outcome variance matters at least as much as headline awards.

The legal path has already shown friction

The clearest example is the reversal of the $60 million Mead Johnson verdict because the jury received incorrect instructions. That alone breaks the shortcut from one large verdict to a new baseline.

The bellwether process makes that unevenness explicit. Bellwether trials began in 2025, with additional trials scheduled for 2026. Abbott also won the first three on summary judgment, and Abbott and Reckitt won a key Missouri case. Those results do not mean liability has disappeared; they show that the legal path is selective, not automatic.

Bears can still point to potentially reaching £2 billion in exposure, and Reuters noted it's unclear when investors can leave the infant formula litigation problems behind. But if the next round of cases keeps producing mixed results, today's pricing may be assuming too much worst-case alignment.

Reckitt's core business still looks operationally intact

The latest operating readout argues for patience rather than capitulation. In the half year, Reckitt delivered +2.7% core LFL net revenue growth with a 60.9% core gross profit margin. More encouragingly, Q2 Core Reckitt Q2 LFL net revenue growth reached +4.2%, while Core + MJN Q2 LFL net revenue growth held a 23.6% adjusted operating profit margin. Group Group Adjusted diluted EPS was 152.1p. That is not the profile of a franchise under structural attack.

Stronger core economics also matter because they buy time. They support the cash generation needed to manage litigation, fund divestments if needed, and preserve flexibility for capital returns if the overhang starts to clear.

Management's challenge is separating the core from the litigation overhang

That is why management now faces a harder task than simple damage control.

The split-strategy debate

After the legal scare hit sentiment, Reckitt moved to sell some home-cleaning brands and may exit its baby milk division. The intent is straightforward: remove the part of the story that is dragging on the valuation of the rest of the business.

The difficulty is timing. Reuters noted it's unclear when investors can leave the infant formula litigation problems behind. Until that timing becomes clearer, management remains caught between two pressures: moving slowly enough to preserve credibility, and moving quickly enough to stop the legal stain from compressing the whole group.

What needs to happen for the stock to rerate

The setup improves only if the next two investor touchpoints reduce uncertainty faster than headline fear fades. The first checkpoint is the 27 Oct 2026 Q3 Trading Update. The second is the 19 Nov 2026 Reckitt Focus On: North America session.

What to watch

• Core resilience holds. Any noticeable slip in the Q3 read would make it harder to argue that the legal scare is confined to one part of the business.
• North America gets more specific. With bellwether trials are set for 2026 and nearly 1,000 similar cases are pending, investors need a clearer framework for exposure, timing, and reserves.
• Divestment timing tightens. Management is already exploring exits to remove the overhang, but Reuters noted it's unclear when investors can leave the litigation problems behind.

If legal outcomes turn harsher or management keeps struggling to clarify timing, the stock may remain cheap for a reason.

This remains a watchlist re-rating idea, not a blind buy-the-dump setup

After Reckitt's more than 15% one-day drop, the investment case depends less on proving that litigation risk does not exist than on showing that it is becoming more understandable and more contained.

What would support a rerating

• Trigger: The 27 Oct 2026 Q3 Trading Update keeps the core story intact, and the 19 Nov 2026 Reckitt Focus On: North America session gives investors a firmer handle on timing, reserves, and exposure.
• Signposts: Management speaks in specifics as bellwether trials are set for 2026, rather than relying on broad reassurance.
• Invalidation: If management continues to talk around the issue, or if the 2026 trial cycle produces harsher and more consistent plaintiff outcomes, the market may simply be pricing risk correctly.